secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059460
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024
--------------------------------------------------------------------------------

- SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.
- CanGarooRM antibiotic-envelope 510(k) submission; positive FDA interactions; clearance anticipated Q2 2024.
- Net loss $18.0M includes $9.6M non-cash warrant revaluation; adjusted EBITDA loss improved to $3.6M.
- Cash balance $12.6M; preparing for CanGarooRM commercial launch in H2 2024.
- Overall net sales $6.7M (+5% YoY); cardiovascular sales declined 56% due to LeMaitre distribution transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/0001104659-24-059460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/tm2414063d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer